Laboratory News and Research

RSS

Human immune system can help predict recurrence, overall breast cancer survival

A study published in Cancer Discovery, the newest journal of the American Association for Cancer Research, debuting here at the AACR 102nd Annual Meeting 2011, held April 2-6, showed how evaluating the immune response in the tumor microenvironment may help researchers better target therapy in breast cancer.

4 Apr 2011

Men who consume digoxin have 24% reduced risk of prostate cancer

Johns Hopkins scientists and their colleagues paired laboratory and epidemiologic data to find that men using the cardiac drug, digoxin, had a 24 percent lower risk for prostate cancer. The scientists say further research about the discovery may lead to use of the drug, or new ones that work the same way, to treat the cancer.

4 Apr 2011

Researchers discover immune system can help predict breast cancer survival

A team of researchers at the University of California, San Francisco has discovered a new way to predict breast cancer survival based on an "immune profile" - the relative levels of three types of immune cells within a tumor. Knowing a patient's profile may one day help guide treatment.

4 Apr 2011

Sickle cell trait can cause sudden death in young African-American athletes

The sickle cell trait could be a cause-albeit rare-of sudden death in young African-American competitive athletes, most commonly during football training, according to a scientific poster that will be presented at the American College of Cardiology Scientific Sessions, April 1-3, in New Orleans.

4 Apr 2011

Life Technologies launches new TaqMan Mutation Detection Assays

Life Technologies Corporation today announced the launch of its TaqMan Mutation Detection Assays -- highly sensitive and novel molecular analysis research tools with the precision to detect a single mutant molecule hiding in a background of 1 million normal copies.

4 Apr 2011

QIAGEN to acquire Cellestis

QIAGEN N.V. has reached an agreement to acquire Cellestis Limited for approximately A$341 million in cash, providing QIAGEN with access to a novel "pre-molecular" technology that offers a new dimension in disease detection not currently possible with other diagnostic methods.

From QIAGEN Manchester Limited 4 Apr 2011

Scientists identify digoxin as possible therapy for prostate cancer

Scientists have identified digoxin as a possible therapy for prostate cancer, using a combination of laboratory science and epidemiology that is unprecedented in its cooperative nature.

4 Apr 2011

New ‘nanotech’ weapon against drug-resistant superbugs

Scientists at the Institute of Bioengineering and Nanotechnology (IBN) and IBM Research – Almaden have developed the first biodegradable polymer nanoparticles to combat drug-resistant superbugs, such as Methicillin-Resistant Staphylococcus aureus (MRSA). These nanoparticles can selectively kill the bacteria without destroying healthy red blood cells, and being biodegradable, have great potential to treat infectious diseases in the body. This was reported today in the leading scientific journal, Nature Chemistry [(2011) DOI: 10.1038/nchem.1012].

3 Apr 2011

Stem Cell Action Coalition issues urgent appeal to Minnesota Governor for SCNT research

The Stem Cell Action Coalition issued an urgent appeal to Minnesota Governor Mark Dayton to veto any legislation that contains any impediment to lawful embryonic stem cell research in the state.

2 Apr 2011

Transgenomic to present study results of high-sensitivity cancer mutation assays at AACR

Transgenomic, Inc. announced today that its scientists have completed studies employing the company's high-sensitivity cancer mutation assays using two proprietary technologies, Ice COLD-PCR and BLOCker-Sequencing. Results from these studies will be presented at the American Association for Cancer Research meeting in Orlando, Florida, April 2-6, 2011.

2 Apr 2011

Report shows a continued decline in diagnoses, deaths for many types of cancers

Once again, the Annual Report to the Nation on the Status of Cancer shows a continued decline in diagnoses and deaths for many types of cancers. This encouraging news can be attributed primarily to preventive measures such as cessation of smoking and improved diet, and early detection.

2 Apr 2011

Rsearchers define new step that controls programmed cell death in cancer cells

When cells find themselves in a tight spot, the cell cycle regulator p21 halts the cell cycle, buying cells time to repair the damage, or if all else fails, to initiate programmed cell death.

2 Apr 2011

PLC's RenalGuard System REMEDIAL II trial final results to be presented at ACC conference

PLC Systems Inc., a company focused on innovative medical device technologies, today reported that final results from the REMEDIAL II investigator-sponsored clinical trial of its RenalGuard System™ in Italy are scheduled to be presented at 11:57 a.m. CT on Monday, April 4, 2011, at the American College of Cardiology's 60th Annual Scientific Session & Expo in New Orleans, Louisiana. Additionally, PLC will be demonstrating RenalGuard at its booth at the conference.

2 Apr 2011

Scientists celebrate successful start up of pioneering EMMA accelerator

A brand new technology that promises a range of applications from treating cancer to powering safer nuclear reactors has reached another world first in its development. This milestone was confirmed yesterday, 31 March 2011, at the Science and Technology Facilities Council's Daresbury Laboratory in Cheshire.

2 Apr 2011

Loss of SKIP sensitizes cancer cells to apoptotic effects of DNA damage-inducing anticancer drugs

When cells find themselves in a tight spot, the cell cycle regulator p21 halts the cell cycle, buying cells time to repair the damage, or if all else fails, to initiate programmed cell death. In contrast to other stress-induced genes, which dispense with the regular transcriptional entourage, p21Cip1 still requires SKIP, a transcription elongation factor that also helps with the editing of transcripts, to be expressed, found researchers at the Salk Institute for Biological Studies.

2 Apr 2011

Hospira introduces enhanced TheraDoc clinical surveillance system

Hospira, a leading provider of clinical information and medication delivery technologies, today announced the launch of its enhanced TheraDoc™ clinical surveillance system, used by hospitals to help improve patient safety and prevent adverse events such as healthcare-associated infections (HAIs).

2 Apr 2011

Twenty-four facilities earn Certified Urgent Care Center designation

Twenty-four more facilities have just received the Certified Urgent Care Center designation awarded by the Urgent Care Association of America. The Certified Urgent Care program helps the public identify urgent care centers and promotes and advances the urgent care industry.

1 Apr 2011

Pediatric health care experts to meet at Pediatric Nursing annual conference

Pediatric nurses are the frontline health care providers for children and adolescents, many of whom suffer from serious illnesses. Because the specialty calls for high-level critical thinking skills, nurses must constantly stay on top of the latest advances in care.

1 Apr 2011

Neogenix Oncology to present laboratory studies of NEO-101 at AACR Annual Meeting

Neogenix Oncology, Inc. announced today that members of its scientific staff will present laboratory studies of NEO-101, a novel monoclonal antibody in development to diagnose and treat pancreatic and colorectal cancers.

1 Apr 2011

CPRIT awards $12.6M grant to Gulf Coast Consortia to develop new cancer treatments

The Gulf Coast Consortia has been awarded a grant of more than $12.6 million from the Cancer Prevention Research Institute of Texas to launch a collaborative program that brings together researchers with the common purpose of developing new cancer treatments.

1 Apr 2011